Live Analyst Rating Changes 35907 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/James Gordon CFA
BARC

James Gordon CFA

Barclays
Wall Street Analyst
★★★★☆
#344
on 13Foresight · ranked by our own returns
64%
Success Rate
+0.1%
Average Return
36 of 56 calls profitable · -0.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 64% of James Gordon CFA's ratings turned a profit when each position was held for 1 year — averaging +0.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

77 Buy 38 Hold 36 Sell
James's Stock Coverage 16 ratings · 2026-09-30
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
CH:GALD
Galderma Group AG
 Sep 30, 2026 BUY Strong Buy
+11.3% avg upside
11 analysts
$220.00
32.74% Upside
 · ·
GB:GSK
GlaxoSmithKline
 Sep 29, 2026 SELL Hold
+5.0% avg upside
26 analysts
$1800.00
1.69% Downside
 · ·
GB:0QW0
arGEN X
 Sep 21, 2026 BUY Strong Buy
-25.5% avg upside
25 analysts
$1100.00
30.12% Upside
 · ·
DE:SRT3
Sartorius
 Sep 08, 2026 BUY Strong Buy
+6.9% avg upside
19 analysts
$300.00
15.57% Upside
 +9.1% ·
GB:0QIU
Novo Nordisk
 Sep 08, 2026 HOLD Hold
+61.2% avg upside
29 analysts
$300.00
19.18% Upside
 · ·
CH:ROP
Roche Holding AG
 Sep 08, 2026 BUY Buy
-1.7% avg upside
24 analysts
$430.00
23.21% Upside
 +3.6% ·
CH:NOVN
Novartis AG
 Sep 08, 2026 HOLD Buy
-7.6% avg upside
32 analysts
$130.00
8.41% Upside
 +7.3% ·
FR:SAN
Sanofi
 Sep 08, 2026 HOLD Buy
+35.6% avg upside
30 analysts
$83.00
14.35% Upside
 -3.3% ·
CH:SDZ
Sandoz Group Ltd
 Sep 08, 2026 BUY Buy
-4.5% avg upside
12 analysts
$93.00
31.32% Upside
 +5.0% ·
GB:HIK
Hikma Pharmaceuticals
 Sep 08, 2026 HOLD Strong Buy
+48.8% avg upside
9 analysts
$1700.00
5.05% Upside
 +3.6% ·
NL:LKFT
Lakefront Biotherapeutics NV
 Sep 08, 2026 SELL Sell
+94.5% avg upside
17 analysts
$22.00
16.68% Downside
 -8.8% ·
GB:AZN
AstraZeneca
 Sep 07, 2026 BUY Strong Buy
+20.7% avg upside
28 analysts
$16000.00
30.25% Upside
 +5.7% ·
GB:0MGB
Genmab A/S
 Aug 10, 2026 BUY Buy
-8.7% avg upside
25 analysts
$2500.00
7.80% Upside
 · ·
GMAB
Genmab
 Aug 07, 2026 BUY Strong Buy
+79.2% avg upside
27 analysts
 — +13.2% ·
ARGX
Argenx Se
 Jul 24, 2026 BUY Strong Buy
-15.0% avg upside
48 analysts
$950.00
1.01% Downside
 +5.0% ·
SE:SOBI
Swedish Orphan Biovitrum AB
 Jul 03, 2026 BUY Strong Buy
+2.4% avg upside
7 analysts
$530.00
20.38% Upside
 -9.1% ·
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
James Gordon CFA — Frequently Asked Questions
How accurate are James Gordon CFA's stock ratings?
Based on the calls 13Foresight could measure, about 64% of James's ratings were profitable over a one-year hold, with an average return of +0.1% per rating, or -0.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is James ranked on 13Foresight?
James Gordon CFA is currently ranked #344 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does James cover?
James most recently has ratings on CH:GALD, GB:GSK, GB:0QW0, DE:SRT3, GB:0QIU, CH:ROP, CH:NOVN, FR:SAN, CH:SDZ, GB:HIK, NL:LKFT, GB:AZN and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.